top of page

35+ YEARS IN MEDICAL DEVICE | PHARMACEUTICAL | BIOTECHNOLOGY | DIAGNOSTICS

Insights and News Curated for Life Science Experts by Life Science Experts....

Go back to...

Executive Spotlights

Lesson’s Learned from Building out the Commercial Organization

SK Life Science breaks through Covid barriers to bring epilepsy drug to market

Lutronic’s Focus on Change during the Pandemic

From Big Pharma to Startup: What are the Challenges?

The View from Olympus: How This MedTech Leader Approached the Pandemic

DENTALEZ COO Heather Trombley on Reinvigorating the Company

Seqirus Exec on Vaccine Differentiation

Zimmer Biomet VP on Covering the Territory

How Teleflex Grew its Market Value 4x in 6 Years

Admedus COO David St. Denis on Courage, Commitment and Conversation

1 min read

Beacon Therapeutics Appoints Dr. Lance Baldo as CEO

London and Cambridge, MA, July 24, 2024 (PRNewswire) -- Beacon Therapeutics has appointed Dr. Lance Baldo as CEO and Thomas Biancardi as CFO. Dr. Baldo has extensive biopharmaceutical experience, including roles at Genentech and Freenome. Biancardi will start his role as CFO on August 1, 2024.

Read full article here.

Recent Posts

Zenflow Secures $24M in Sercies C- Funding

South San Francisco, CA, November 18, 2024 (Globe Newswire) -- Zenflow, Inc., a leader in medical device innovation for urological...

Nobias Therapeutics Appoints Patrick Dougherty as CEO to Lead Next Phase of Growth

Philadelphia, November 14, 2024 (PRNewswire) -- Nobias Therapeutics has named Patrick Dougherty as its Chief Executive Officer, marking...

Metsera Secures $215M in Series B Funding to Advance Obesity and Metabolic Disease Portfolio

New York, November 13, 2024 (Business Wire) -- Metsera has raised $215 million in Series B financing, led by Wellington Management and...

Comments

Life Science Headlines

Zenflow Secures $24M in Sercies C- Funding

Nobias Therapeutics Appoints Patrick Dougherty as CEO to Lead Next Phase of Growth

Metsera Secures $215M in Series B Funding to Advance Obesity and Metabolic Disease Portfolio

Julie Eastland Appointed CEO of Zentalis Pharmaceuticals to Lead Advancement of Azenosertib in Oncology

Boston Scientific Acquires Axonics for $3.7B to Expand Urology Portfolio

Axonis Therapeutics Secures $115M Series A to Advance Neuromedicine Pipeline

Celltex Therapeutics Welcomes Anita Perry as CEO

Alpha-9 Oncology Secures $175M Series C to Drive Radiopharmaceutical Innovation in Cancer Treatment

I-Mab Appoints Dr. Sean Fu as Permanent CEO to Lead Advancement of Cancer Immunotherapy Programs

AbbVie Acquires Aliada Therapeutics for $1.4B to Expand Alzheimer's Research Portfolio

bottom of page